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analysis, sunitinib has a 45.9% and a 64.9% probability of being
cost-effective compared with IFN-a at the threshold of $50,000
and $100,000/QALY, respectively. Survival, sunitinib drug costs
and cost of best supportive care were the key drivers of the
model. CONCLUSION: Sunitinib is a cost-effective alternative
to IFN-a as ﬁrst-line treatment in mRCC, with cost-effectiveness
ratios within the established threshold that society is willing to
pay for health beneﬁts (i.e. $50,000–100,000/LY or QALY).
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OBJECTIVE: Chemotherapy-induced anemia (CIA) is often
treated with erythropoiesis-stimulating agents (ESAs). This study
assessed the cost consequence of Q3W_DA administration
(500 mg) compared to QW_EA or QW_EB from a German soci-
etal perspective.METHOD:Adecision-treemodel was developed
in MSExcel based on the results of a European retrospective
observational study that included data from 786 patients with
non-myeloid malignancy and CIA over a 16-week period. Tran-
sition probabilities, average hemoglobin (Hb) value over treat-
ment period, number of blood transfusions, drug administrations,
transfusion, response to treatment and ESA administration set-
tings were used. Unit costs were applied to medical resources used
and to patients’ time, further speciﬁed by a panel of 11 German
clinical experts. Time was valued at gross hourly wage rate. Both
time andmedical costs were extracted from ofﬁcial sources (EBM)
and adjusted to 2006€. A 5000-replications probabilistic sensitiv-
ity analysis was performed with @RISK® using distributions for
probabilities (binomial), medical resources used (normal), time
(normal) and outcome measures (normal). RESULTS: The differ-
ence in hemoglobin between treatments was: Q3W_DA minus
QW_EA, 0.13 g/dL (95%CI:-0.151, 0.420) andQ3W_DAminus
QW_EB, 0.19 g/dL (95%CI:-0.0168, 0.393). Q3W_DA resulted
in comparable mean Hb-change over time to QW_EA and
QW_EB. Lower costs were observed for Q3W_DA: -197€
[95%CI:-972, 572] vs. QW_EA and -203€ [95%CI:-722, 294]
vs. QW_EB. Sensitivity analysis for Q3W_DA revealed 56% of
the replications vs. QW_EA and 75% vs. QW_EB with better Hb
values and lower costs (dominant); 25% vs. QW_EA and 21% vs.
QW_EB with higher costs and better Hb values. CONCLU-
SIONS: This analysis with real-life information showed that
treatment of CIAwithQ_3WDAwas effective and less costly than
QW_EA and QW_EB. A decision in favor of Q3W_DA has the
highest probability to be beneﬁcial from the German societal
perspective.
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OBJECTIVES: To estimate the cost-effectiveness of cetuximab in
combination with radiotherapy (ERT) compared to radiotherapy
alone (RT), for the treatment of locally advanced head and neck
cancer in patients for whom chemoradiotherapy is inappropriate
or intolerable in the UK. METHODS: A modelled economic
evaluation calculated the incremental cost per quality-adjusted
life year (QALYs) gained with ERT compared to RT. Resource
utilisation and survival data were extracted from an international
phase-III trial of ERT. Assumptions regarding costs of care were
drawn from estimates by an expert clinical panel. Overall sur-
vival and progression-free survival times were extrapolated
beyond the trial period using statistical models. Patient survival
was stratiﬁed into health states deﬁned by adverse event status in
the acute phase and disease status post-treatment. Utility values
for the health states were obtained from a survey of oncology
nurses using the EQ-5D. Estimates of individual costs and out-
comes were estimated for each patient in the trial and overall
mean values calculated for the incremental analysis between the
treatment groups. The analysis was conducted from the perspec-
tive of the NHS. Costs and outcomes were discounted at 3.5%.
RESULTS: In the lifetime analysis, ERT patients were estimated
to gain an extra 1.26 QALYs compared to RT patients. From the
public establishment perspective, this translated into an incre-
mental cost per QALY gained of 6,390. Shortening the analysis
to the timeframe of the clinical trial (5 years) raised the ICERs to
19,951 per QALY gained respectively. Bootstrap simulation
and sensitivity analysis showed that the ICERs were robust to
changes in the key variables. CONCLUSION: Results of the
modelled economic evaluation strongly suggest that ERT offers a
good value-for-money alternative in the treatment of locally
advanced head and neck cancer in the UK.
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OBJECTIVES: Bladder cancer is the ﬁfth leading type of cancer
diagnosed in Belgium. Early detection is key in improving sur-
vival. Hexvix, by inducing tumor ﬂuorescence during cys-
toscopies, improves lesion detection, delineation and therefore
also lesion resection. The cost-effectiveness of adding Hexvix to
standard white light cystoscopy in the diagnosis and manage-
ment of non-muscle invasive bladder cancer was assessed from
the Belgian health care payers’ perspective. METHODS: A
Markov model with a 10 year time horizon, describing manage-
ment patterns and resulting outcomes in patients with suspected
bladder cancer, was developed in Excel. Treatment patterns and
clinical evolution of high (HR), medium (MR) and low (LR) risk
patients were derived from European treatment guidelines and
further validated by a panel of 3 Belgian urologists. By using
Hexvix in diagnostic cystoscopies bladder cancer could poten-
tially be detected at an earlier stage (4% HR diagnosed in MR
and 4% MR in LR) and resection could be more complete
resulting in lower recurrence rates (HR: -50%; MR: -40% and
LR: -30%; based on data obtained with an unlicensed, less
readily taken up ﬂuorescent molecule). Ofﬁcial tariffs were
applied to medical resources identiﬁed. An annual discount rate
of 3% for future cost and 1.5% for effects was applied. Results
were expressed as cost per life year gained (LYG). RESULTS:
Using this model, compared to standard white light cystoscopy
adding Hexvix, in diagnostic and therapeutic cystoscopies,
increased survival per patient could be 0.09 years at an incre-
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mental cost of €496, resulting in an incremental cost-effectiveness
ratio of €5470/LYG. LYG and incremental costs were respec-
tively most sensitive to time-horizon and the effect of Hexvix on
recurrence rate (€3,251/LYG to €25,549/LYG). CONCLUSION:
Compared to standard white light cystoscopy alone, in this hypo-
thetical model adding Hexvix to this procedure appears to be
cost-effective in Belgium from the health care payer’s perspective.
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OBJECTIVES: To determine the cost-effectiveness of sunitinib
malate versus best supportive care (BSC) after failure of cytokine
immunotherapy from the perspective of the Belgian public payers
(INAMI/RIZIV). METHODS: A Markov model was constructed
to simulate disease progression after failure on ﬁrst-line cytokine
therapy. Patients entered the model receiving sunitinib plus BSC
or BSC alone. The model had 3 disease states (progression-free
survival, tumor progression and move to BSC, and death) and
used monthly cycles. Outcomes in the model were valued in
terms of progression-free life years (PFLYs) and life years (LYs)
gained. The cost-effectiveness measures were cost per PFLY and
cost per LY saved. The effectiveness parameters for sunitinib
were taken from a phase II clinical trial (RTKC-0511-014). To
estimate survival for patients receiving palliative/supportive care,
data from a SEER-Medicare analysis and a study of previously-
treated patients with mRCC who were candidates for second-line
therapy (Motzer et al., 2004) were combined. Medical costs in
2006 prices were considered from the perspective of the RIZIV/
INAMI. Resource utilization was based on expert opinion from
a modiﬁed Delphi panel consisting of seven Belgian physicians
specialized in mRCC. Utilities were derived from published lit-
erature. The model incorporates the expensive cost of the termi-
nal stage (last 4 weeks of life). Future costs were discounted at
3% and effects at 1.5% in line with the Belgian pharmacoeco-
nomic guidelines. The time horizon was lifetime (10 years).
RESULTS: Treatment with sunitinib was associated with an
average gain of 5.13 PFLYs and 1.11 LYS per patient. The
incremental cost-effectiveness ratio of sunitinib versus BSC was
€7,665 per PFLY and €35,389 per LY gained. CONCLUSION:
Given the assumptions and limitations of this model, if the value
of a life year gained for cytokine-refractory mRCC patients is at
least €35,389 sunitinib should be considered a cost-effective
therapy.
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OBJECTIVES: Primary prophylaxis with granulocyte-colony
stimulating factors, used in the ﬁrst and subsequent cycles of
chemotherapy, is recommended by the 2006 ASCO and EORTC
guidelines when the overall risk of febrile neutropenia (FN)
is 20%. We evaluated the cost-effectiveness of pegﬁlgrastim
versus ﬁlgrastim used for 11 days (as used in clinical trials) and
6 days (often used in clinical practice) in patients with aggressive
non-Hodgkin’s lymphoma (NHL) receiving CHOP-21 chemo-
therapy in Italy. METHODS: A decision-analytic model was
constructed from a health care payer’s perspective with a life-
time model horizon. Costs (2006 value) including drugs, drug
administration, FN-related hospitalisations, and subsequent
medical costs were acquired from ofﬁcial price lists or literature.
FN risk, FN case-fatality, relative dose intensity (RDI), and
impact of RDI on survival were based on data from a compre-
hensive literature review and expert panel validation. Using data
from a meta-analysis and several observational studies, we esti-
mated that the absolute risk of FN in patients receiving peg-
ﬁlgrastim decreased from 19.6% to 13.1% (6.5 percentage
points) versus 11-day ﬁlgrastim, and from 25.1% to 13.1% (12
percentage points) versus 6-day ﬁlgrastim. NHL mortality and
all-cause mortality were from literature. Sensitivity analyses were
performed on key parameters. RESULTS: Pegﬁlgrastim was cost
saving compared with 11-day ﬁlgrastim (€5053 versus €7465).
Compared with 6-day ﬁlgrastim, the incremental cost-
effectiveness ratio (ICER) was €475 per FN event avoided or €5
per 1% decrease in absolute risk of FN. Pegﬁlgrastim achieved
0.112 more discounted life-years (LY) at a minimal cost increase
of €57 (€5053 versus €4996) per person, yielding an ICER of
€513/LY gained. Results were most sensitive to the relative risk of
FN for ﬁlgrastim versus pegﬁlgrastim. CONCLUSION: In Italy,
pegﬁlgrastim was cost saving compared with 11-day ﬁlgrastim
and appeared to be cost-effective compared with ﬁlgrastim used
for 6 days per cycle of CHOP-21.
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COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR
ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY
INDUCED NAUSEA ANDVOMITING
Ruiz MA1, Garrido J1, García Pulgar MS2,Alvarez Sanz C2
1Universidad Autónoma de Madrid, Madrid, Spain, 2Roche Farma,
Madrid, Spain
OBJECTIVES: To study the incremental cost-effectiveness of
two 5HT3 receptor antagonists-granisetron (GR) against
ondansetron (ON)- in prevention treatment of Chemotherapy
induced nausea and vomiting (CINV). METHODS: Prospective,
multi-center, observational study on 325 naïve patients recruited
at 8 Spanish Oncology Services. Consecutive patients undergoing
1st cycle with moderate to highly emetogenic chemotherapy,
and scheduled antiemetic treatment based on GR or ON were
enrolled. After chemotherapy (day 0), daily maximum nausea
intensity and number of vomiting episodes were self-recorded
during 5 more days in a diary card. Acute CINV was deﬁned as
developed in day 0, and delayed CINV as developed or persisting
in days 1–5. Antiemetic “full” response was deﬁned as: no emesis
and no/mild nausea. Differences between GR and ON in adverse
event costs, emergency visits, or other concomitant treatments
were negligible. Only antiemetic drug direct costs were consid-
ered. Incremental Cost-Effectiveness Ratio (ICER) was computed
for 1,000 and 10,000 bootstrap samples. Mean ICER values,
bootstrap percentiles and cost-effectiveness scatterplots were
used for comparison. RESULTS: No differences were found in
acute treatment effectiveness (GR = 78.7%, ON = 79%) making
impossible to interpret ICER values. Direct mean cost was some-
what higher for GR = 36.9€ (SD = 35.3) than for ON = 34.1€
(SD = 34.2). Delayed effectiveness was higher in GR (51.8%)
than in ON (42.7%) arm, with lower mean (90%IC) costs in
GR = 19.54€ (16.57, 22.6) than in ON = 55.26€ (46.4, 64.2)
group. Bootstrap ICER mean value was 353.1 (P10 = 1120.8,
P90 = 85.7). Scatterplots in the cost-effectiveness space showed
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